Health Condition 1: B461- Rhinocerebral mucormycosis
Conditions
Interventions
Intervention1: Outpatient antifungal therapy: Outpatient anti fungal therapy will be started after initial stabilisation of comorbidities and disease process in invasive sinonasal mucurmycosis patient
Sponsors
All India Institute of Medical Sciences, New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: Patient giving written informed consent All stable cases of invasive sinonasal mucormycosis (orbital, minimal intracranial extension included), after initial management with surgical debridement and medical therapy. Patient with local residence/ ready for commute. Good cognition and family support Stable - Clinical improvement; No major infusion reaction requiring stopping of drug administration Adequate intake, output, blood parameters (S. K+, elctrolytes, S. creatinine, Urea) for the past 72 hours
Exclusion criteria
Exclusion criteria: Not consenting Gross residual disease after debridement Lack of family support and cognition Unable to commute or do not have local residence
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of twice weekly outpatient antimicrobial therapy (OPAT) with Liposomal Amphotericin B and its comparison with standard long term in patient anti fungal therapy for invasive sinonasal mucurmycosis at 6 weeks post therapy.Timepoint: Efficacy of twice weekly outpatient antimicrobial therapy (OPAT) with Liposomal Amphotericin B and its comparison with standard long term in patient anti fungal therapy for invasive sinonasal mucurmycosis at 6 weeks post therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Relationship between serum drug levels and drug toxicityTimepoint: 6 weeks During Inpatient/ Outpatient therapy;Response rate of patients who become candidate for OPAT. Timepoint: trial completion. | — |
Countries
India
Contacts
Public ContactDr Poonam Sagar
All India Institute of Medical Sciences, Delhi
Outcome results
None listed